Genmab Outlicenses HuMax-IL8

Genmab A/S 

30.05.2012 08:46
---------------------------------------------------------------------------

Media Release

- HuMax-IL8 licensed to Cormorant Pharmaceuticals

Copenhagen, Denmark; May 30, 2012 - Genmab A/S (OMX: GEN) announced today it
has granted an exclusive, worldwide license to its HuMax(R)-IL8 antibody to
Cormorant Pharmaceuticals.  Under the terms of the agreement, Genmab will
receive an upfront payment and will be entitled to milestone payments and
royalties on net sales.  Cormorant intends to evaluate HuMax-IL8 for treatment
of select cancers and will be responsible for all future costs of developing,
manufacturing and commercializing HuMax-IL8. 

'We are pleased to enter this license agreement with Cormorant Pharmaceuticals
who will work towards resuming the development of HuMax-IL8,' said Jan van de
Winkel, Ph.D., Chief Executive Officer of Genmab. 

This agreement does not affect Genmab's 2012 financial guidance.

About HuMax-IL8
HuMax-IL8 is a high affinity fully human IgG1,κ antibody directed towards IL-8.
IL-8 is a major mediator of inflammation, a potent chemoattractant for white
blood cells called neutrophils, as well as an important factor in angiogenesis.
HuMax-IL8 effectively blocks binding of IL-8 to neutrophils and inhibits
neutrophils from migrating towards sites of inflammation via a process known as
chemotaxis. HuMax-IL8 also potently inhibits IL-8 induced neutrophil
activation. In pre-clinical studies, HuMax-IL8 has been shown to inhibit tumor
growth in tumor models using primary human tumors in immunodeficient mice. 

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer.  Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(R)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development.  Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates.  Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies.  For more information visit
www.genmab.com. 

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication 
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words 'believe',
'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Media Release nor to confirm such
statements in relation to actual results, unless required by law. 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax(R)-EGFr;
HuMax(R)-IL8; HuMax(R)-TAC; HuMax(R)-CD38; HuMax(R)-TF; HuMax(R)-TF-ADC;
HuMax(R)-Her2;
HuMax(R)-cMet, HuMax(R)-CD74, DuoBody(TM) and UniBody(R) are all trademarks of Genmab
A/S. Arzerra(R) is a trademark of GlaxoSmithKline. 

Media Release no. 03
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
News Source: NASDAQ OMX



30.05.2012 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Genmab A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0010272202
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------